In an accompanying editorial, Dawn Hershman, M.D., and Alfred I. Neugut, M.D., Ph.D., of Columbia University Medical Center in New York write that it has been difficult to predict which patients are most likely to develop cardiotoxicity following anthracycline therapy. Neither randomized clinical trials nor studies that rely on large administrative databases are adequate for addressing the issue. Therefore, Ryberg's study is an important step to helping physicians personalize cancer care for their patients.
"If we can better predict who is at greatest risk for toxicity and who is not, we may be able to comfortably offer standard treatment to a larger percentage of the population," the editorialists write.
Lapatinib Reduces Brain Metastases in Mouse Model of Metastatic Breast Cancer
Lapatinib reduces the number of large brain metastases in a mouse model of metastatic breast cancer, relative to untreated mice.
Symptomatic brain metastases affect between 10 and 20 percent of women with metastatic breast cancer, and the problem is particularly common for women whose tumors overexpress the HER2 protein. However, trastuzumab, an antibody that blocks the HER2 protein activity and is the standard of care for HER2-posi
|Contact: Liz Savage|
Journal of the National Cancer Institute